A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone - Kremer, J M; Cohen, S; Wilkinson, B E (Arthritis Rheum, 2012)
et al.